Interestingly, Wu et al. reported that 8 weeks of fenofibrate treatment for insulin resistance in men with dyslipidemia reduced serum levels of RBP4 by 30%, which were correlated with reduced body weight and increased insulin sensitivity [25]. The gene discussed is RBP4; the disease is metabolic syndrome.